Boiron France / Boiron France

Belkins
Boiron is a family-owned and independent pharmaceutical company. We are specialized in the manufacture of homeopathic medicines of very high quality for a century. Present in more than 50 countries, with 3,708 employees, we develop with rigor and passion our project for health. Boiron is an independent, family-run pharmaceutical laboratory.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Business Wire | March 06, 2020

news image

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Read More

VIGILANZ LAUNCHES COVID QUICK START SOFTWARE THAT GIVES HOSPITALS CUSTOMIZABLE REAL-TIME ALERTS AND REPORTS TO MANAGE VIRAL OUTBREAKS

Prnewswire | May 21, 2020

news image

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Read More

HIT Consultant | April 07, 2020

news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

Prnewswire | August 18, 2020

news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

Business Wire | March 06, 2020

news image

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Read More

Prnewswire | May 21, 2020

news image

VIGILANZ LAUNCHES COVID QUICK START SOFTWARE THAT GIVES HOSPITALS CUSTOMIZABLE REAL-TIME ALERTS AND REPORTS TO MANAGE VIRAL OUTBREAKS

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Read More